Disease-relevant molecules that cannot be pharmacologically targeted are sometimes referred to as undruggable, and in cancer, a number of proteins fall into this category. With innovation and new technologies, researchers make breakthroughs that turn evasive targets into druggable ones. Recent successes in establishing therapeutics against mutant oncoproteins, such as KRAS, transform the treatment landscape for patients and clinicians. A scientist who takes a unique approach to clinical trial design demonstrates how targeted small molecules are shifting drug discovery paradigms in oncology to better treat pancreatic cancer.

In this episode, Deanna MacNeil from The Scientist’s Creative Services Team spoke with David Hong, the Dougie Johnson Endowed Professor and clinical medical director of the clinical trial research unit at MD Anderson Cancer Center, to learn more.

More on this topic

The Scientist Speaks is a podcast produced by The Scientist’s Creative Services Team. Our podcast is by scientists and for scientists. Once a month, we bring you the stories behind news-worthy molecular biology research. This month's episode is sponsored by NanoTemper.


David Hong

David S. Hong, MD
Dougie Johnson Endowed Professor
Clinical Medical Director, Clinical Trial Research Unit
Deputy Chair, Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
University of Texas, MD Anderson Cancer Center

NanoTemper Technologies creates biophysical tools for drug discovery and development scientists who need to tackle challenging characterizations. If you’re facing challenges with affinity screening, molecular interactions, or protein stability, let’s talk. To handle your most challenging drugs and drug targets like PROTACs, Intrinsically Disordered Proteins, and fragment libraries, turn to NanoTemper’s Dianthus instrument. Learn more at nanotempertech.com.

Sponsored by